1
|
Shikha S, Lee YW, Doyle PS, Khan SA. Microfluidic Particle Engineering of Hydrophobic Drug with Eudragit E100─Bridging the Amorphous and Crystalline Gap. Mol Pharm 2022; 19:4345-4356. [PMID: 36268657 DOI: 10.1021/acs.molpharmaceut.2c00714] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Co-processing active pharmaceutical ingredients (APIs) with excipients is a promising particle engineering technique to improve the API physical properties, which can lead to more robust downstream drug product manufacturing and improved drug product attributes. Excipients provide control over critical API attributes like particle size and solid-state outcomes. Eudragit E100 is a widely used polymeric excipient to modulate drug release. Being cationic, it is primarily employed as a precipitation inhibitor to stabilize amorphous solid dispersions. In this work, we demonstrate how co-processing of E100 with naproxen (NPX) (a model hydrophobic API) into monodisperse emulsions via droplet microfluidics followed by solidification via solvent evaporation allows the facile fabrication of compact, monodisperse, and spherical particles with an expanded range of solid-state outcomes spanning from amorphous to crystalline forms. Low E100 concentrations (≤26% w/w) yield crystalline microparticles with a stable NPX polymorph distributed uniformly across the matrix at a high drug loading (∼89% w/w). Structurally, E100 incorporation reduces the size of primary particles comprising the co-processed microparticles in comparison to neat API microparticles made using the same technique and the as-received API powder. This reduction in primary particle size translates into an increased internal porosity of the co-processed microparticles, with specific surface area and pore volume ∼9 times higher than the neat API microparticles. These E100-enabled structural modifications result in faster drug release in acidic media compared to neat API microparticles. Additionally, E100-NPX microparticles have a significantly improved flowability compared to neat API microparticles and as-received API powder. Overall, this study demonstrates a facile microfluidics-based co-processing method that broadly expands the range of solid-state outcomes obtainable with E100 as an excipient, with multiscale control over the key attributes and performance of hydrophobic API-laden microparticles.
Collapse
Affiliation(s)
- Swati Shikha
- Critical Analytics for Manufacturing Personalized-Medicine, Singapore-MIT Alliance for Research and Technology, Singapore138602, Singapore
| | - Yi Wei Lee
- Department of Chemical and Biomolecular Engineering, National University of Singapore, 4 Engineering Drive 4, Singapore117576, Singapore.,NUS Graduate School for Integrative Sciences & Engineering, National University of Singapore, Singapore119077, Singapore
| | - Patrick S Doyle
- Critical Analytics for Manufacturing Personalized-Medicine, Singapore-MIT Alliance for Research and Technology, Singapore138602, Singapore.,Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts02139, United States.,Harvard Medical School Initiative for RNA Medicine, Boston, Massachusetts02215, United States
| | - Saif A Khan
- Department of Chemical and Biomolecular Engineering, National University of Singapore, 4 Engineering Drive 4, Singapore117576, Singapore
| |
Collapse
|
2
|
Wojtalewicz S, Vizmeg J, Erickson S, Lade C, Shea J, Sant H, Magda J, Gale B, Agarwal J, Davis B. Evaluating the influence of particle morphology and density on the viscosity and injectability of a novel long-acting local anesthetic suspension. J Biomater Appl 2022; 37:724-736. [PMID: 35649287 DOI: 10.1177/08853282221106486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Proper pain management is well understood to be one of the fundamental aspects of a healthy postoperative recovery in conjunction with mobility and nutrition. Approximately, 10% of patients prescribed opioids after surgery continue to use opioids in the long-term and as little as 10 days on opioids can result in addiction. In an effort to provide physicians with an alternative pain management technique, this work evaluates the material properties of a novel local anesthetic delivery system designed for controlled release of bupivacaine for 72 hours. The formulation utilizes solid-lipid microparticles that encapsulate the hydrophobic molecule bupivacaine in its free-base form. The lipid microparticles are suspended in a non-crosslinked hyaluronic acid hydrogel, which acts as the microparticle carrier. Two different particle manufacturing techniques, milling and hot homogenization, were evaluated in this work. The hot homogenized particles had a slower and more controlled release than the milled particles. Rheological techniques revealed that the suspension remains a viscoelastic fluid when loaded with either particle type up to 25% (w/v) particles densities. Furthermore, the shear thinning properties of the suspension media, hyaluronic acid hydrogel, were conserved when bupivacaine-loaded solid-lipid microparticles were loaded up to densities of 25% (w/v) particle loading. The force during injection was measured for suspension formulations with varying hyaluronic acid hydrogel concentrations, particle densities, particle types and particle sizes. The results indicate that the formulation viscosity is highly dependent on particle density, but hyaluronic acid hydrogel is required for lowering injection forces as well as minimizing clogging events.
Collapse
Affiliation(s)
- Susan Wojtalewicz
- Department of Mechanical Engineering, 14434University of Utah, Salt Lake City, UT, USA.,Rebel Medicine Inc., Salt Lake City, UT, USA
| | - Jonathon Vizmeg
- Rebel Medicine Inc., Salt Lake City, UT, USA.,Department of Biomedical Engineering, 14434University of Utah, Salt Lake City, UT, USA
| | | | - Caleb Lade
- Rebel Medicine Inc., Salt Lake City, UT, USA
| | - Jill Shea
- Department of Surgery, 14434University of Utah, Salt Lake City, UT, USA
| | - Himanshu Sant
- Department of Mechanical Engineering, 14434University of Utah, Salt Lake City, UT, USA
| | - Jules Magda
- Department of Chemical Engineering, 14434University of Utah, Salt Lake City, UT, USA
| | - Bruce Gale
- Department of Mechanical Engineering, 14434University of Utah, Salt Lake City, UT, USA
| | - Jayant Agarwal
- Rebel Medicine Inc., Salt Lake City, UT, USA.,Department of Surgery, 14434University of Utah, Salt Lake City, UT, USA
| | - Brett Davis
- Rebel Medicine Inc., Salt Lake City, UT, USA
| |
Collapse
|